Healthcare benefits cover prescription medications through a structured framework called a Pharmacy Benefit Manager (PBM) model. It manages drug costs, formulary tiers, and access. Most employer-sponsored health plans link prescription coverage to their medical plan via a PBM, a third-party administrator that negotiates with drug manufacturers, sets pricing, and processes claims. Prescription drug spending increased 7.9% to $467 billion in 2024, and drug costs have ranked among the fastest-growing components of employer health benefit spending for years.
The Foundation: Formularies and Tiers
Every health plan with prescription coverage uses a formulary: a list of approved medications organized into cost tiers. The formulary determines what an employee pays out-of-pocket through copays, coinsurance, or deductibles. Typical tier structures include:
- Tier 1: Generic drugs - Lowest copays (e.g., $10-$15). These are chemically equivalent to brand-name drugs but far cheaper.
- Tier 2: Preferred brand-name drugs - Higher copays (e.g., $30-$50). These are drugs on the PBM's preferred list, often with negotiated rebates.
- Tier 3: Non-preferred brand-name drugs - Highest copays or coinsurance (e.g., $60-$80+). These drugs lack preferred status and often require prior authorization.
- Specialty tier - Reserved for high-cost biologics, injectables, or complex therapies. Cost-sharing can be 20-30% coinsurance or flat fees exceeding $150 per month.
Employers can customize these tiers to manage costs, but most plans adopt a standard PBM formulary unless they negotiate custom rebates or exclusions.
How Members Pay: Co-pays, Deductibles, and Coinsurance
Prescription benefits are typically integrated with the medical plan's deductible and out-of-pocket maximum, but the structure can vary:
- Co-pay model: Fixed fee per prescription (e.g., $15 for generic, $40 for brand). This is common in large group plans but less common in high-deductible health plans (HDHPs).
- Coinsurance model: Member pays a percentage of the drug cost (e.g., 20% for Tier 2 drugs). This is typical with self-funded plans and HDHPs.
- Combination models: Many plans apply the deductible first to prescriptions, then switch to copays or coinsurance once the deductible is met.
Key insight: In traditional BUCA (Blues, United, Cigna, Aetna) plans, pharmacy costs are often baked into the premium. But in self-funded plans, the employer bears the risk, which makes PBM contract terms critical.
The Role of the PBM: Rebates, Spread Pricing, and Transparency
PBMs like Express Scripts, OptumRx, and Caremark act as middlemen between drug manufacturers, pharmacies, and plan sponsors. Their revenue comes from:
- Rebates: Drug manufacturers pay PBMs to get their drugs on preferred tiers. These rebates are often not fully passed to the employer, creating a hidden cost.
- Spread pricing: PBMs charge the plan more than they pay the pharmacy, pocketing the difference. That's employer waste, plain and simple.
- Administrative fees: A per-claim or per-member fee for processing claims.
Employer pain point: Traditional PBMs profit from complexity. WellthCare™, the first Health-to-Wealth™ Benefit System, counters this with transparent, compliance-grade recordkeeping for every verified preventive action, rewarding employees with store dollars and retirement contributions. Solutions like WellthCare Pharmacy™ replace the PBM with pass-through pricing, where the plan pays the same price the PBM paid the pharmacy plus a transparent administrative fee, so spread and rebate games disappear. WellthCare's transparent, aligned model typically saves 20-40% on drug costs while improving adherence through automated refill reminders.
Preventive Care and Medication Coverage
Under the Affordable Care Act (ACA), most health plans must cover certain preventive medications without cost-sharing. That list draws on four sources: USPSTF recommendations with an A or B grade, ACIP-recommended immunizations, and guidelines supported by the Health Resources and Services Administration (HRSA) for women and children. Statins for primary prevention of heart disease fall under a USPSTF recommendation; contraceptives come from the HRSA-supported Women's Preventive Services Guidelines. The no-cost-sharing list is still narrow. For most chronic medications (e.g., insulin, blood pressure drugs), employees still face copays or coinsurance.
WellthCare's model fills this gap. By rewarding preventive actions, including medication adherence, with spendable dollars at the WellthCare Store™ and automatic retirement contributions, the system creates a financial incentive for employees to take their prescriptions as prescribed. This reduces waste, lowers claims, and builds long-term wealth.
Specialty Drugs: The Rising Cost Crisis
Specialty drugs (e.g., for cancer, rheumatoid arthritis, multiple sclerosis) account for more than half of total drug spending while representing less than 2% of prescription utilization. Typical coverage models include:
- Prior authorization (PA): Doctors must prove the drug is medically necessary.
- Step therapy: Patients must try cheaper alternatives first.
- Quantity limits: Restrict how much medication can be dispensed per month.
- Exclusive specialty pharmacies: Members are forced to use PBM-owned hubs, limiting choice.
Aligned alternatives: WellthCare Complete™ integrates pharmacy into a transparent self-funded plan, bypassing PBMs entirely and using the employer's own data through the WellthCare Readiness Index™ to project savings. For employers, this means projected savings of 30-45% compared with traditional major carriers, while employees keep their store dollars and automatic retirement contributions.
Compliance and Reporting Considerations
Prescription benefits must comply with ERISA (reporting and fiduciary duties), ACA (preventive coverage mandates), and state drug-pricing transparency laws. TPAs and PBMs must provide:
- Detailed drug-spend reports (e.g., by therapeutic class)
- Rebate pass-through details (increasingly demanded by fiduciaries)
- Medication adherence metrics for wellness programs
WellthCare's patent-pending system automates compliance-grade recordkeeping by tracking preventive actions and medication use, giving employers a documented record without relying on manual audits.
FTC Action and State Transparency Rules on PBM Rebates
Pressure on the traditional PBM model now comes from regulators as well as employers. In September 2024, the Federal Trade Commission filed an administrative complaint against the three largest PBMs, Caremark Rx, Express Scripts, and OptumRx, along with their group purchasing organizations. The complaint alleges the PBMs used rebating practices that artificially inflated insulin list prices and excluded lower-priced insulins in favor of higher-rebate products. State drug-pricing transparency laws also push PBMs to disclose rebate and pricing information.
For employers, this raises the standard for PBM contracts. A contract that hides rebate details is harder to defend when regulators are demanding disclosure. Plan sponsors are responding by asking for pass-through terms and audit rights, the same conditions a transparent, aligned model builds in from the start.
Conclusion: The Shift Toward Aligned Pharmacy Models
Traditional prescription coverage via PBMs carries hidden costs, misaligned incentives, and complex tiers. The shift is toward transparent, integrated systems where pharmacy supports health rather than generating hidden margin. Solutions like WellthCare Pharmacy™ and WellthCare Complete™ show that aligning employee health, wealth, and cost savings is already happening. For employers tired of opaque PBM games, the path forward is clear: demand transparency, integrate prevention, and choose a system where healthcare pays you back.
This article is for general information only and is not legal, tax, or medical advice. Employers should consult their own advisors.